Can we predict eye damage after stem cell transplants?
NCT ID NCT07794800
First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time
Summary
This study follows 340 people who have had a stem cell transplant to understand eye complications that can occur afterward, known as chronic graft-versus-host disease. Researchers will track how often these eye problems happen, what factors increase the risk, and how they affect patients' quality of life. The goal is to gather information that could help doctors better detect and manage these complications in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve how doctors detect and manage eye complications after stem cell transplants, potentially leading to better quality of life for patients.
- What could go wrong
- This is an observational study, so it cannot prove what causes the eye complications or test new treatments. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 340 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients after all-HSCT
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥14 years, both genders eligible; * First allogeneic hematopoietic stem cell transplantation; * 100 days post-transplantation, with donor hematopoietic stem cell engraftment confirmed; * The subject or their legally authorized representative has provided full informed consent, signed the informed consent form, and is willing to complete subsequent follow-up visits Exclusion Criteria: * Preexisting moderate-to-severe ocular surface disease prior to transplantation; * Active ocular infection; * Presence of other ocular conditions that, in the opinion of the ophthalmologist, may significantly affect the diagnosis of chronic ocular graft-versus-host disease, the evaluation of ocular surface parameters, or the completion of long-term follow-up; * Patients with active hematologic malignancies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic graft versus host disease in eye are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China